Cash-strapped European governments keep pressing for lower drug prices. Meanwhile, price cuts in China, Russia and four other top emerging markets reduced their revenue by 4 percent, but total emerging markets sales hit $2.62 billion, up 8 percent.
Pfizer maintained its 2012 forecast for adjusted earnings per share of $2.14 to $2.24 and revenue of $58 billion to $60 billion.
It remains on track to sell its nutrition business for $11.85 billion to Swiss food and drink giant Nestle SA by 2013's first half, and for the potential separation of its animal health business. The company said it expects to register with the Securities and Exchange Commission by mid-August for a potential initial public offering of up to 20 percent of what will be called Zoetis.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.